Results 71 to 80 of about 122,680 (303)

Cost‐Effectiveness of Low‐Dose Colchicine Prophylaxis When Starting Allopurinol Using the “Start‐Low Go‐Slow” Approach for Gout: Evidence From a Noninferiority Randomized Double‐Blind Placebo‐Controlled Trial

open access: yesArthritis Care &Research, EarlyView.
Objective The aim of this study was to investigate the cost‐effectiveness of low‐dose colchicine prophylaxis for preventing gout flares when starting allopurinol using the “start‐low go‐slow” approach. Methods Participants with gout, fulfilling the American College of Rheumatology recommendations for starting urate‐lowering therapy and with serum urate
Yana Pryymachenko   +4 more
wiley   +1 more source

Current Literature [PDF]

open access: yes, 1982
Material appearing below is thought to be of particular interest to Linacre Quarterly readers because of its moral, religious, or philosophic content. The medical literature constitutes the primary, but not the sole source of such material.
Catholic Physicians\u27 Guild
core   +12 more sources

Event program [PDF]

open access: yes, 2011
UNLV Undergraduates from all departments, programs and colleges participated in a campus-wide symposium on April 16, 2011. Undergraduate posters from all disciplines and also oral presentations of research activities, readings and other creative ...
Reiber, Carl, Booker, Nicholle
core   +5 more sources

Should desperate volunteers be included in randomised controlled trials? [PDF]

open access: yes, 2005
Randomised controlled trials (RCTs) sometimes recruit participants who are desperate to receive the experimental treatment. Some claim this practice is unethical for at least three reasons. The first is that the notion of equipoise, which is often used
Allmark, P. J., Mason, S.
core   +2 more sources

Considerations for Issues of Regression to the Mean and Contextual Effects in Clinical Trials for Pain in Rheumatic Diseases

open access: yesArthritis Care &Research, EarlyView.
Recently, there has been growing discussion about how to best assess pain in clinical trials in rheumatic diseases. Reliable measurement of pain outcomes is essential for accurately determining the effectiveness of treatments. Although pain intensity is the most common measure of change in pain trials, other pain‐related measures, such as pain ...
Yen T. Chen   +4 more
wiley   +1 more source

Widespread use of pure and impure placebo interventions by GPs in Germany [PDF]

open access: yes, 2017
Aim. To collect data on the use of placebo interventions by GPs in Germany. Methods. A questionnaire was mailed to 400 randomly selected GPs in Bavaria.
Fässler, Margrit   +3 more
core  

A Placebo-Controlled, Pseudo-Randomized, Crossover Trial of Botanical Agents for Gulf War Illness: Resveratrol (Polygonum cuspidatum), Luteolin, and Fisetin (Rhus succedanea) [PDF]

open access: gold, 2021
Kathleen S. Hodgin   +7 more
openalex   +1 more source

Effectiveness and safety of baricitinib for juvenile idiopathic arthritis associated uveitis or chronic anterior antinuclear antibody positive uveitis

open access: yesArthritis Care &Research, Accepted Article.
Objectives Evaluate the efficacy and safety of baricitinib in paediatric patients with active JIA‐U or chronic anterior ANA‐positive uveitis, who had an inadequate response to MTX or bDMARDs. Methods JUVE‐BRIGHT was an open‐label, active‐controlled, Phase‐3 multicentre trial which utilized a novel design, including 1:1 randomization to an active ...
Athimalaipet V. Ramanan   +7 more
wiley   +1 more source

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. [PDF]

open access: yes, 2004
BACKGROUND: An open-label study indicated that selective depletion of B cells with the use of rituximab led to sustained clinical improvements for patients with rheumatoid arthritis. To confirm these observations, we conducted a randomized, double-blind,
Close, DR   +7 more
core   +1 more source

Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studies [PDF]

open access: gold, 2022
Christopher T. Ritchlin   +15 more
openalex   +1 more source

Home - About - Disclaimer - Privacy